Cardiogen vs Vesugen
Moderate Research vs Moderate Research
synergistic Complementary cardiovascular bioregulators - Cardiogen for heart, Vesugen for vessels.
Molecular Data
Cardiogen Vesugen
Weight 460 Da 390 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Not established
Chain 4 amino acids 3 amino acids
Type Tetrapeptide bioregulator Tripeptide bioregulator
Key Benefits
Cardiogen
01 Supports cardiac tissue repair and regeneration
02 Regulates cardiovascular gene expression
03 Improves myocardial function
04 May support post-cardiac event recovery
05 Epigenetic mechanism for targeted action
06 Works at DNA/nuclear level
07 Part of comprehensive anti-aging protocols
08 Well-researched Khavinson peptide
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
Cardiogen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Cardiogen
Generally well-tolerated
Minimal side effects reported
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Active cardiac emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Cardiogen Vesugen
Status Moderate Research Moderate Research
References 3 studies 3 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.